3D CNN-CVAE and LSTM-guided de novo design of rotigotine derivatives targeting dopamine D1 and D3 receptors in restless legs syndrome

Sinan Eliaçık, Nouman Ali · 2026

Read 3D CNN-CVAE and LSTM-guided de novo design of rotigotine derivatives targeting dopamine D1 and D3 receptors in restless legs syndrome by Sinan Eliaçık, Nouman Ali (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0356614.txt.

Description

Sinan Eliaçık and Nouman Ali designed new drug candidates by computer in 2026 for restless legs syndrome, a disorder that drives an urge to move the legs, worst at night. Their target receptors are dopamine D1 and D3, since dopamine signaling is deeply involved in the condition. Starting from rotigotine, a drug already used for it, they aimed to design improved derivatives from scratch, a process called de novo design.

Their pipeline combines a three dimensional convolutional network with a generative model and a sequence model to propose and refine candidate molecules. Computer design of this kind can explore far more chemical possibilities than a laboratory, leaving bench scientists a short list worth making and testing.

Catalog record

CREATORSinan Eliaçık, Nouman Ali
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE149515
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0356614

Browse the full library · About the Tower of Babel